Interim PET scans identify HL patients with better outcomes

Print Friendly, PDF & Email


Micrograph showing Hodgkin lymphoma
Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after upfront BEACOPP without impairing disease control, according to final results of the AHL2011-LYSA study. BEACOPP, compared to ABVD, improves progression-free survival (PFS) but not overall survival (OS) and is associated... [Read Article]
Print Friendly, PDF & Email

Umbralisib has ‘distinct’ safety profile

Print Friendly, PDF & Email


Micrograph showing CLL
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell malignancies. Researchers said the safety profile of umbralisib “was distinct from that of other PI3Kδ inhibitors,” as it produced few immune-mediated adverse events (AEs). Umbralisib also produced an objective response... [Read Article]
Print Friendly, PDF & Email

‘Long-term benefits’ with nivolumab in cHL

Print Friendly, PDF & Email


Micrograph showing
Hodgkin lymphoma
Nivolumab can provide “long-term benefits” in patients with relapsed or refractory classical Hodgkin lymphoma (cHL), according to researchers. Extended follow-up of the CheckMate-205 study showed that nearly 70% of patients responded to nivolumab. The median duration of response was 17 months, and the median progression-free survival (PFS) was 15... [Read Article]
Print Friendly, PDF & Email

Art education benefits blood cancer patients

Print Friendly, PDF & Email


Doctor and patient
Photo courtesy of CDC
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including those undergoing transplant. The BVAI involved an educator teaching patients art technique one-on-one for approximately 30 minutes. After a single session, patients had significant improvements in... [Read Article]
Print Friendly, PDF & Email

FDA approves label update for nivolumab

Print Friendly, PDF & Email


Nivolumab (Opdivo)
Photo from Business Wire
The US Food and Drug Administration (FDA) has updated the label for nivolumab (Opdivo®) to include new dosing and administration information. Nivolumab can now be given at 480 mg infused every 4 weeks for most approved indications, in addition to the previously approved dosing schedule of 240 mg... [Read Article]
Print Friendly, PDF & Email

Study confirms higher risk of infection with CB transplant

Print Friendly, PDF & Email


Amandeep Godara, MD
Results of a large, retrospective analysis support the notion that patients who receive cord blood (CB) transplants have a higher risk of infection than other hematopoietic stem cell transplant (HSCT) recipients. Investigators found that CB recipients had a significantly higher risk of bacterial, viral, and fungal infections in the early post-transplant... [Read Article]
Print Friendly, PDF & Email